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Canine distemper virus (CDV) is a pathogen which affects members of the Canidae family, causing an acute, 
often fatal, systemic disease. CDV is an RNA virus of the family Paramyxoviridae that contains two envelope 
glycoproteins: F and HA. In this study, we focused on the envelope glycoprotein F as the main target for 
neutralizing antibodies produced after infection or vaccination. The complete coding region of the protein (60 
kDa) was expressed in the methylotrophic yeast Pichia pastoris, obtained in a recombinant form and secreted 
to the culture medium. Later, to analyze its immunogenicity, the protein was combined with an oily adjuvant 
and used to inoculate mice. The results provide evidence supporting a potential application of this 
recombinant protein as a subunit vaccine. 
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1.Introduction 
Canine distemper virus (CDV) belongs to the genus Morbillivirus of the family Paramyxoviridae [1, 2]. 
Infection by CDV induces clinical signs associated with the respiratory, gastrointestinal and central nervous 
systems. In addition, CDV induces high morbidity and mortality in dogs and exhibits an ever-increasing host 
range in wild aquatic and terrestrial carnivores, often with devastating consequences [3, 4, 5]. The genome of 
CDV is a single-stranded, negative-sense RNA molecule of approximately 15.5 kb in length that encodes 
eight proteins [6]. The genomic RNA is tightly associated with three viral proteins: the nucleocapsid, RNA 
polymerase and phosphoprotein. The envelope is constituted by a double lipid layer derived from the host 
cell, whose inner face contains the matrix protein and whose outer face contains two glycoproteins: 
hemagglutinin (H) and the fusion protein (F) [7]. The fusion protein F is a type I glycoprotein [8, 9] that is 
synthesized as a pre-protein of 662 amino acids (pre-F0). However, some authors have suggested that the 
initiation of translation of F might occur either in the first initiation codon (AUG1) or a second initiation 
codon (AUG61) [10, 11]. Both pre-F0 (1) and pre-F0 (61) are translocated within the lumen of the 
endoplasmic reticulum and are cleaved between amino acids 135 and 136 by a signal peptidase (SPase) [11]. 
This result into two unusually long signal peptides of 75 or 135 amino acids depending on the start codon and 
a second immature precursor F0 that trimerizes in the endoplasmic reticulum and is cleaved by furin in the late 
Golgi apparatus and trans-Golgi network to yield active complexes containing covalently linked F1 and F2 
subunits [12]. Afterwards, the mature protein is inerted into the plasma membrane of the infected cell [11]. 
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The estimated molecular weight of F0 is 60 kDa, whereas that of the F1 subunit is approximately 41 
kDa and F2 subunit is approximately 26 kDa [13]. F1 has an N-terminal fusion peptide (which is inserted into 
the cell plasma membrane during fusion) [14, 15], a transmembrane C-terminal domain and two hepta 
repetitions (HRA) and (HRB), which are critical for membrane fusion [16], whereas the F2 subunit is about 
100 amino acids long and is associated with the regulation of fusion [17]. The main role of the fusion protein 
is to insert itself into the plasma membrane of thehost cell, favouring the fusion between the plasma 
membrane and the envelope of the viral particle [18]. 
Considering that protection against CDV is based mainly on the immune response against envelope 
glycoproteins (fusion protein and hemagglutinin), in the present study, we analyzed the ability of the 
methylotrophic yeast Pichia pastoris to express the fusion protein F0. We also made a preliminary evaluation 
of its immunogenic properties in mice, to determine whether the recombinant protein could be used as an 
alternative method to produce a subunit vaccine against canine distemper.  
 
2.Materials and methods 
2.1.Strains, plasmids, cells and culture media 
The CDV strain Onderstepoort (i.e. the strain used for the CDV vaccine) was used as a standard laboratory 
strain [13]. Vero cells were grown in Eagles’s minimum essential medium -MEM- (Gibco) supplemented 
with 10 or 2% fetal calf serum –FCS- (Internegocios). Escherichia coli strain TOP10, P. pastoris strain 
GS115, and the pPIC9 expression vector from Invitrogen Co. (USA) were used. Yeast extract-peptone-
dextrose –YPD-  medium (1% yeast extract, 2% peptone, 2% dextrose), minimal  glycerol –MGY- medium 
(1.34% Yeast Nitrogen Base–YNB-, 1% glycerol, 4 x 10-5% biotin), buffered methanol medium–BMM- 
(100mM potassium phosphate pH 6, 1.34% YNB, 0.5% methanol,4 x 10-5% biotin), Luria Bertani plates 
containing 100 µg/mL ampicillin (LB-amp), plates with minimal dextrose –MD- (1.34% YNB, 2% dextrose, 
4 x 10-5% biotin and 1.5% agar) and plates with minimal methanol–MM- (1.34% YNB, 0.5% methanol, 4 x 
10-5% biotin and 1.5% agar) as described in the Invitrogen Pichia expression kit (USA) were used as culture 
media.  
 
2.2.Amplification of the CDV fusion protein gene by RT-PCR 
Viral RNA was extracted from the CDC strain grown in Vero cells until infected cells showed 80-90% 
cytopathic effects. Then, 300 µL of supernatant was mixed with 500 µL of TRIzol (GibcoBRL) and 220 µL of 
chloroform (Merck) and vortexed vigorously for 10 min. This mixture was then centrifuged at 12,000 rpm 
and 4 °C for 10 min. The supernatant obtained (600 µL) was transferred onto a new tube containing 750 µL 
Isopropanol (Anedra) and, after mixing by inversion, centrifuged at 12,000 rpm and 4 °C for 15 min. 
Subsequently, the supernatant was discarded and the pellet obtained was washed with 750 µL of 70% cold 
ethanol. Finally, the RNA was resuspended in 15 µL of nuclease-free water (Biodynamics) and quantified by 
spectrophotometry. Retrotranscription was carried out using a reverse transcriptase MMLV (Promega). The
viral RNA (5 µg) and random hexamer primers (1 µg) (Promega) were denatured at 65 °C for 5 min and then 
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cooled to 4 °C. To synthesize the first-strand cDNA, the RNA and primers were mixed with 5 µL reaction 
buffer (5x), 1 µL of MMLV enzyme (200 U/µL) (Promega), 1 µL of dNTPs (200 µM) and 2 U of RNase 
inhibitor (Promega) and 3 µL of H2O. The mixture was incubated at 37 °C for 60 min. PCR was then 
performed with 5 µL cDNA product, 0.2 µM of each forward primer (PFf) 
5’AGGCCTATGCCAGTCTCTTTCTTTGTT 3’ and reverse primer (PFr) 5’ 
GCGGCCGCTCAGTGTGATCTCACATA 3’ (IDT) containing the StuI and NotI (Promega) sites 
(underlined), respectively, and 1.25 U Taq DNA polymerase (Fermentas) for 29 cycles (95 °C for 1 min, 
annealing at 59 ºC for 2 min and extension at 72 °C for 2 min). Products were then run in 1.5% agarose with 
TBE buffer and then stained with ethidium bromide. The full-length PCR products from the F gene were 
sequenced using the same primers by automatic sequencing (Facultad de Ciencias Exactas y Naturales, 
Universidad de Buenos Aires, Argentina). 
 
2.3.Expression in P. pastoris 
Plasmid pCR2.1TOPO-F0 was initially generated by inserting a PCR fragment of the F0 gene into the 
pCR2.1TOPO vector (Invitrogen). Then, a 1620-bp StuI–NotI fragment isolated from pCR2.1TOPO-F0 was 
then subcloned into the SnaBI-NotI-plasmid pPIC9 (Invitrogen). The StuI and SnaBI digestion produces blunt 
ends and after ligation of both products pPIC9 and F0, ORF F0 is in reading frame with the export signal to the 
cell outside. The resulting plasmid was named pPIC9-F0. The F0 reading frame was placed under the control 
of the AOXI (methanol inducible) promoter. In addition, the resulting protein was fused to the α-factor, which 
directs the secretion of the protein to the culture medium. The ligation mixture of pPIC9-F0 was transformed 
into chemically competent E. coli bacteria strain TOP10 and then grown in LP-amp. Then pPIC9-F0 plasmid 
DNA was purified with a commercial kit (Promega) from the bacterial colonies and digested with the EcoRV 
restriction enzyme (Promega) to verify the presence of the F0 fragment. To generate homologous 
recombination between the yeast genome and the transfer vector, pPIC9-F0 was linearized with the BglII 
enzyme (Promega). For this purpose, 5 µg of vector, 3 µL of enzyme and 4 µL of buffer were used in a final 
volume of 40 µL and incubated at 37 °C for 18 h. The enzyme was then inactivated at 65 °C for 15 min. P. 
pastoris (GS115) cells were transformed with 1 µg of linearized pPIC9-F0 in Cell-Porator (Gibco) through a 
480V pulse, with a capacitance of 10 µF and low resistance (Ωlow). Then, 1 mL of cold sorbitol was added to 
each cuvette and 600 µL was plated in MD plates. Then, the plates were incubated 30 °C 48 h until the 
appearance of the colonies. Colonies grown on these plat s were spiked onto minimal medium with methanol 
without histidine plates (MM) and grown for 48 h at 30 °C. After incubation, the presence of the F0 fragment 
was confirmed by colony PCR using specific primers to the AOX1 region: 5’AOX1 (5’ GAC TGG TTC CAA 
TTG ACA AGC 3’) and 3’AOX1 (5’ GCA AAT GGC ATT CTG ACA TCC 3’). 
 
2.4.Sequence analysis 
To confirm the sequence of the insert, plasmids were s quenced using M13 primers.  Sequences were aligned 
in MEGA program version 4.0 using the ClustalW algorithm and compared with the reference strain 
Ondersterpoot (Acc. X65509.1, AF305419.1, AF378705.1). The predicted amino acid sequence was 
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compared with reference strain and analysis of N-glycosylation sites was performed (NetNGlyc -
www.cbs.dtu.dk/services/NetNGlyc/-). This program predicts asparagines to be N-glycosylated according to 
the Asn-Xaa-Ser/Thr sequons (where Xaa is not Pro), with a threshold of 0.5.  
 
2.5.Small-scale protein expression 
To check the expression of the F0 recombinant protein, liquid cultures of the GS115-F0 clones obtained were 
performed in 100 mL of  MGY medium and incubated on an orbital shaker at 120 rpm for 20 h until reaching 
an OD(600 nm) of 4-6. The yeasts were then collected under sterile conditions and centrifuged at 3000 rpm
for 15 min at room temperature. Expression was induce  in BMM medium. Cell pellets were resuspended in 
1/10 of the initial volume and cultured at 30 °C for 5 days with gentle shaking (120 rpm). Samples of ecreted 
proteins were taken every 24 hours and analyzed by SDS-PAGE and Western blot. The expression remained 
induced for 108 hours by addition of 100% methanol every 24 h until a final concentration of 0.5% v/v. 
Culture supernatants were harvested by centrifugation and proteins were precipitated with 60% (NH4)2SO4 by 
centrifugation at 5000 rpm for 60 min. The ammonium sulphate was then removed by extraction with 
methanol/chloroform (partially purified protein). 
 
2.6.Detection of the recombinant F-protein by SDS PAGE-Western blot 
Partially purified protein obtained after 72, 96 and 108 h induction were mixed with 2X Laemmli sample 
buffer containing 2% (2-Mercaptoethanol), boiled at 99 °C for 2 min, and fractionated on 10% SDS 
polyacrylamide gels under denaturing conditions. Separated proteins were stained with Coomassie Brilliant 
Blue R250 (Sigma). For Western blot analyses, the proteins separated by SDS-PAGE were electrophoretically 
transferred to nitrocellulose membranes (Sigma) in a Trans-blot Semi Dry Electroforetic Transfer Cell 
(BioRad) according to the manufacturer’s recommendations. After blocking in PBS containing 0.1% Tween-
20 (PBS-T) and 5% of skim milk powder at room temperature for 1 h, the membranes were incubated with a 
polyclonal mouse antibody anti-CDV glycoproteins produced previously in the Laboratory, in PBS-T–3% 
skim milk powder at room temperature for 2 h. This serum was obtained after immunization of three 
conventional six-week-old BALB/c mice with the commercial attenuated canine distemper vaccine -0.05 mL 
by intramuscular route- (Novibac Puppy DP MSD) with two boosters every 15 days. Subsequently, the 
membranes were washed in PBS-T at least three times followed by incubation with 1/500 dilution of 
horseradish peroxidase-conjugated anti-mouse antibody (Sigma Aldrich) in PBS-T–3% skim milk powder at 
room temperature for 1.5 h. After extensive washing, the membranes were placed in 0.3 mg/mL of DAB 
solution and H2O2 for 15 min until the appearance of the bands. 
 
2.7.Immunization experiment in mice  
To evaluate the immunogenicity of the recombinant pro ein in vivo, an immunization scheme was performed 
in mice. The partially purified protein was run in a SDS-PAGE (in a continuous comb) and cut and eluted 
from gel at 4 °C overnight in PBS (passive diffusion) (concentrated protein).  Subsequently, the protein was 
quantified by UV spectrophotometry. For this purpose, the protein was diluted in sterile PBS to a final 
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concentration of 10 µg/mL. Specific pathogen-free six-week-old male BALB/c mice were provided by the 
Laboratory of Experimental Animals (School of Veterina y Sciences, National University of La Plata, Buenos 
Aires, Argentina) and kept in conventional animal facilities. Animal handling and all experimental procedures 
were carried out in compliance with the recommendations of the Guide for the Care and Use of Laboratory 
Animals of the National Research Council of Argentina. Three groups of three BALB/c mice were 
immunized three times with purified F0 (group A), 0.03 mL of 10
5 TCID50/mL (tissue culture infectious 
dose) attenuated commercial vaccine (group B) or PBS-Specol (group C). Experimental animals were reduc 
to a minimum, in accordance with laws related to anim l welfare. Immunizations were performed 
intramuscularly in the inguinal plexus with 0.5 µg of protein administered, combined with Specol adjuvant in 
equal volumes, every 15 days [19]. Only the first immunization was performed with adjuvant. The animals 
were sacrificed and bled 15 days after the last immunization. To obtain the sera, blood was left to coagulate at 
room temperature and after coagulation the samples were centrifuged at 1000 rpm for 15 min. The sera 
obtained were stored at -20 °C until used. 
 
2.8.Immunogenicity assays 
In order to analyze the immunogenicity of the F0 protein, Western blot was performed. Vero cell cultures 
infected with CDV strain were harvested at 72 h postinfection, lysed directly in loading buffer (crude 
antigen), run in a SDS-PAGE and then transferred onto nitrocellulose membranes as described above [19].
After transfer, the membranes were cut into strips of approximately 0.5 cm and placed in test tubes (1 cm in 
diameter; 10 cm long) containing 2 mL of the blocking solution. Sera from each group were mixed in a single 
pool (A, B, or C) and used in a 1/100 dilution. They were then incubated for 90 min with gentle shaking, 
always taking care that the membranes were immersed in the blocking solution. Then, three washes were 
performed and the membranes further incubated with a 1/500 dilution of the conjugated anti-mouse antibody 
(Sigma). Finally, after three more washes, the strip  were revealed using DAB solution as described above. 
 
2.9.Virus neutralization 
Virus grown in Vero cells showed 80-90% cytopathic effects was frozen twice at -80° C and centrifuged at 
3,000 rpm for 10 min. Infectivity titre of the virus was measured by TCID50/50µL in Vero cells in a 96-wells 
tissue culture plate. After 72 hs of incubation a titre of 103 TCID50/50µL was obtained. Serum samples from 
each inoculated mouse (A, B and C) were heat inactiv ted at 56 °C for 30 min.  Virus neutralization assays 
were performed with serial twofold dilutions of sera prepared using MEM in a 96-well flat-bottomed tissue 
(Nunc, Rochester, NY), mixed with 100 TCID50 in 25 µL and then incubated at 37 °C for 1 h in a 5% CO2, 
followed by addition of 100 µL of Vero cell suspension (3×105 cells/mL) to each well and incubation for 72 
h, as described previously. The VN antibody titre was expressed as the reciprocal of the highest dilution the 
inhibited cytopathic effect completely [20].   
  
3.Results 
3.1.RT-PCR and generation of the recombinant protein in P. pastoris 
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The complete F0 gene of CDV was successfully amplified by RT-PCR from a commercial vaccine strain. The 
correct reading frame of the inserted gene was evaluated by sequencing, using the primer AOX1 F and R. 
Blast (n) analysis of the sequence resulted in 99% homology to the GenBank AF305419.1, AF378705.1 and 
X65509.1 sequences belonging to the gene of the CDV fusion protein corresponding to the Onderstepoort 
strain, and the predicted sequence of the recombinant F0 protein is shown in Figure 1. The recombinant F0 
protein was expressed and identified and the putative N-linked glycosylation sites are same as reference 
strain. A PCR fragment bearing the entire coding region (1624 nt; 537 aa) of the F gene was cloned into the 
expression vector pPIC9, generating a construct expressing the recombinant F0 gene fused to an export 
sequence that allowed releasing the protein to the culture medium. 
 
3.2.Small-scale protein expression and detection by SDS-PAGE/Western blot 
The expression of the F0 recombinant protein was induced by addition of 0.5 % of methanol every 24 h to 
GS115 cells containing the pPIC9-F0 plasmid. Then, purified supernatants as described above were run in 
SDS-PAGE. The recombinant protein was detected in low level by Western blot. The estimated molecular 
weight was about 60 kDa, which corresponded to the molecular weight of the expected F0 protein (Figures 2a 
& 2b).  
 
3.3.Immunogenicity assay  
Purified protein F0 (partially purified and concentrated) was run in a SDS-PAGE in order to check purity 
(Figure 3a). Immunogenic capacity was checked in BALB/c mice. A single band of approximately 60 kDa, 
corresponding to the F0 protein, was detected by Western blot -group A- and in group B more than one band 
(Figure 3b). The virus neutralization antibody titres in mice s ra from groups A and B were relatively low: 
A1 and A2:1/16; A3 1/8; B1: 1/32; B2: 1/16; B3: 1/32. 
 
4.Discussion 
In this study, we were able to clone and express the complete coding region of the CDV F gene. The fusion 
protein F is constituted by two subunits originated from a protein precursor pre-F0 [11], which suggests that 
the peptide is not part of the mature protein. For that reason, we decided to express only the precursor F0, 
eliminating the signal peptide located at the N-terminal of the protein. 
The expression system used to obtain the F0 protein, based on the methylotrophic yeast P. pastoris, 
turned out to be relatively simple and efficient for several reasons. One of these reasons was the simplicity to 
genetically manipulate the system and select the recombinant yeasts by auxotrophy to histidine. The latter 
allowed cloning the genes simply and rapidly. In addition, the insertion of the genes of interest into the yeast 
genome allowed performing cultures of high cell density without requiring a constant selection pressure such 
as an antibiotic [21, 22, 23].   
The expression levels obtained for the F0 protein were low (35 µg/mL); however, the expression 
system in P. pastoris allowed the production of the recombinant polypeptide without the need for as many 
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steps of optimization of expression as those requird for other expression systems [24]. Besides, the 
metabolism of P. pastoris is mainly aerobic and unlike Sacharomyces cereviceae it can grow in fermenters in 
large-scale cultures, reaching very high cell densities. In addition, no phenomena of hyperglycosylation of 
proteins expressed in P. pastoris have been observed that could generate an exacerbated immune response 
preventing their therapeutic use [25]. The recombinant F0 protein showed a molecular weight of about 60 kDa, 
a value that corresponded to that estimated by Iwatsuki et al. (1998) [13] for the glycosylated form. This 
suggests that the recombinant F0 contains some post-translational modification. 
To evaluate the immunogenicity of the recombinant F0 protein, BALB/c mice were used as the in 
vivo model. The protein was combined with an oily adjuvant (Specol) to improve the immune response, 
because many recombinant proteins are usually poor as immunogens. Some authors have used Specol as an 
alternative to Freund's Adjuvant, since its administration causes fewer adverse effects [26, 27].Based on the 
results obtained by Western blot in Figure 3b (line 1), we concluded that the mice inoculated with the F0 
protein produced antibodies that recognized the proteins homonymous to CDV. The use of Specol allowed 
increasing the immune system response of such mice. 
Accessory bands obtained in Western blot (Figure 3b lane 2) may be due to the presence of 
impurities in crude antigen. The non-specificity observed could be due to the fact that the specific antibodies 
against have reacted with protein products expressed in the infected Vero cells used as crude antigen in 
Western blot. One possibility is that CDV vaccine is produced in Vero or similar cells. 
VN titres greater than 1:100 are considered completely protective in domestic canines obtained with 
CDV attenuated virus vaccines. Although in this work we have not been able to achieve titles of that 
magnitude, we must emphasize that the murine model used for the production of specific antibodies does not 
represent the best model for the study of canine distemper. Since we do not have facilities that can produce 
SPF canines, only members of the Mustelidae family as a mink or ferret could have been used as 
replacements, which are very expensive and difficult to keep in captivity. For these reasons we limit ourselves 
to the use of rodents as experimental animals. 
The protection against CDV by vaccination is based primarily on the immune system response 
against envelope glycoproteins (hemagglutinin and fusion protein) [28]. The immunity to the F antigen has 
been shown to block the replication of challenge virus and to prevent the emergence of symptoms in animals 
after virus replication. This suggests that the F antigen may suffice act as an immunogen for protection 
against canine distemper. Attenuated vaccines have been used to prevent CDV infection worldwide, however 
there has been an increase in clinical cases [29, 30, 31]. A recent increase in clinical disease has also been 
detected in Argentina including vaccinated dogs [32].  Despite the above, Pardo et al., 1997 [33], have 
described in their studies that although the levels of antibodies obtained in canines immunized with 
recombinant vaccines were low, they were sufficient to protect them against the challenge of a pathogenic 
CDV strain . 
The results obtained in our study showed that the CDV F protein could be efficiently expressed in the 
P. pastoris system, indicating the potential of F protein expressed in this system as a subunit vaccine 
candidate for the control of the disease. The cost of production and secondary consecuences after vaccination 
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could be reduced by using new immunogens. While the best way to achieve lasting and effective immunity is 
with the use of attenuated virus vaccines, however th y can cause encephalitis [34, 35], or reversion to 
virulent strains, not to mention the low rate of replication of viral strains currently used [36, 37]. Nevertheless, 
use of a subunit vaccine may overcome these disadvantages. 
There is not other studies in family Paramyxoviridae, with the exception on Newcastle virus. Kang et 
al, 2016  [38],  produced the recombinant F protein expressed by P. pastoris as a subunit vaccine candidate 
and considered that is an efficient and economic protein expression system, more suitable for expressing viral 
proteins because of its posttranslational modification. This strategy allows culture time reduction and 
minimizes the cost of production which is important for industrial applications. 
The viral proteins obtained by recombinant technology would allow eliminating the cellular proteins 
found in the CDV attenuated vaccines currently used obtained by successive passages in cell cultures or 
embryonated eggs, reducing adverse reactions, and also reducing production costs such as concentration nd 
viral purification. Significant advantages of this system include proper protein folding, posttranslational 
modifications, and glycosylation of recombinant proteins in the correct sites which is important for protein 
stability systems  [39]. Besides, mammalian expression ystems grow slowly and the relevant nutrient 
requirement is costly and yeasts are widely used for the expression of several proteins in vaccine and
pharmaceutical production. Subunit viral vaccines are completely safe and cost‐effective and for its 
production P. pastoris is more famous than other expression systems as was summarized in a recent review 
(Dengue, Chikungunya, Foot and Mouth disease, SARS and Newcastle Disease)  [40].  Recombinant CDV 
proteins might be useful for the development of safer vaccines for future. At this time our working group is 
expressing other CDV proteins on P. pastoris with promisory results that will be the subject of a comparative 
analysis in the future. 
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Figure 1: Alignment of the predicted amino acid sequences for the F0 protein of the Onderstepoort strains 
from GenBank. The potential glycosylation sites are enclosed by rectangles  
 
Figure 2a: Small scale F0 protein expression analysis by SDS-PAGE. Five-fold concentrated by (NH4)2SO4 
culture supernatants (15 µL) after methanol induction: lane 1: prestained molecular weight marker 
(Fermentas); lane 2: non-transformed P. pastoris (negative control); lane 3: 72 h post-induction; lane 4: 96 h 
post-induction, lane 5: 108 h post-induction 
 
Figure 2b: Small scale F0protein expression by Western blot analysis. Five-fold concentrated by (NH4)2SO4 
culture supernatants (15 µL) after methanol induction: lane 1: non-transformed P. pastoris (negative control); 
lane 2: 72 h post-induction; lane 3: 96 h post-induction, lane 4: 108 h post-induction, lane 5: prestained 
molecular weight marker (Fermentas). As primary antibody mice sera inoculated with commercial attenuated 
canine distemper vaccine was used. 
 
Figure 3a: F0 analysis in SDS-PAGE. Lane 1: partially purified protein; lane 2: concentrated F protein (eluted 
from gel); lane 3: prestained molecular weight marker (Fermentas). 
 
Figure 3b: Western blot analysis using 2 mL of 1/100 dilutions of polyclonal sera of mice inoculated. Crude 
antigen obtained from Vero-inoculated CDV was used. Lane 1: serum pool group A (mice immunized three 
times with concentrated F0), lane 2: serum pool group B (mice immunized with a tenuated commercial CDV 
vaccine), lane 3: serum pool group C (mice inoculated with PBS-Specol), lane 4: prestained molecular weight 
marker (Fermentas). 
 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
 
RecF            MASLFLCSKAQIHWNNLSTIGIIGTDSVHYKIMTRPSHQYLVIKLMPNVSLIDNCTKAEL 60 
AF378705.1      IASLFLCSKAQIHWNNLSTIGIIGTDSVHYKIMTRPSHQYLVIKLMPNVSLIDNCTKAEL 60 
AF305419.1      MASLFLCSKAQIHWNNLSTIGIIGTDSVHYKIMTRPSHQYLVIKLMPNVSLIENCTKAEL 60 
X65509.1        MASLFLCSKAQIHWNNLSTIGIIGTDSVHYKIMTRPSHQYLVIKLMPNVSLIENCTKAEL 60 
                :***************************************************:******* 
 
RecF            GEYEKLLNSVLEPINQALTLMTKNVKPLQSLGSGRRQRRFVGVVLAGAALGVATAAQITA 120 
AF378705.1      GEYEKLLNSVLEPINQALTLMTKNVKPLQSLGSGRRQRRFAGVVLAGAALGVATAAQITA 120 
AF305419.1      GEYEKLLNSVLEPINQALTLMTKNVKPLQSLGSGRRQRRFAGVVLAGVALGVATAAQITA 120 
X65509.1        GEYEKLLNSVLEPINQALTLMTKNVKPLQSLGSGRRQRRFAGVVLAGVALGVATAAQITA 120 
                ****************************************.******.************ 
 
RecF            GIALHQSNLNAQAIQSLRTSLEQSNKAIEEIREATQETVIAVQGVQDYVNNELVPAMQHM 180 
AF378705.1      GIALHQSNLNAQAIQSLRTSLEQSNKAIEEIREATQETVIAVQGVQDYVNNELVPAMQHM 180 
AF305419.1      GIALHQSNLNAQAIQSLRTSLEQSNKAIEEIREATQETVIAVQGVQDYVNNELVPAMQHM 180 
X65509.1        GIALHQSNLNAQAIQSLRTSLEQSNKAIEEIREATQETVIAVQGVQDYVNNELVPAMQHM 180 
                ************************************************************ 
 
RecF            SCELVGQRLGLRLLRYYTELLSIFGPSLRDPISAEISIQALSYALGGEIHKILEKLGYSG 240 
AF378705.1      SCELVGQRLGLRLLRYYTELLSIFGPSLRDPISAEISIQALSYALGGEIHKILEKLGYSG 240 
AF305419.1      SCELVGQRLGLRLLRYYTELLSIFGPSLRDPISAEISIQALIYALGGEIHKILEKLGYSG 240 
X65509.1        SCELVGQRLGLRLLRYYTELLSIFGPSLRDPISAEISIQALIYALGGEIHKILEKLGYSG 240 
                ***************************************** ****************** 
 
RecF            GDMIAILESRGIKTKITHVDLPGKFIILSISYPTLSEVKGVIVHRLEAVSYNIGSQEWYT 300 
AF378705.1      GDMIAILESRGIKTKITHVDLPGKFIILSISYPTLSEVKGVIVHRLEAVSYNIGSQEWYT 300 
AF305419.1      SDMIAILESRGIKTKITHVDLPGKFIILSISYPTLSEVKGVIVHRLEAVSYNIGSQEWYT 300 
X65509.1        SDMIAILESRGIKTKITHVDLPGKFIILSISYPTLSEVKGVIVHRLEAVSYNIGSQEWYT 300 
                .*********************************************************** 
 
RecF            TVPRYIATNGYLISNFDESSCVFVSKSAICSQNSLYPMSPLLQQCIRGDTSSCARTLVSG 360 
AF378705.1      TVPRYIATNGYLISNFDESSCVFVSESAICSQNSLYPMSPLLQQCIRGDTSSCARTLVSG 360 
AF305419.1      TVPRYIATNGYLISNFDESSCVFVSESAICSQNSLYPMSPLLQQCIRGDTSSCARTLVSG 360 
X65509.1        TVPRYIATNGYLISNFDESSCVFVSESAICSQNSLYPMSPLLQQCIRGDTSSCARTLVSG 360 
                *************************:********************************** 
 
RecF            TMGNKFILSKGNIVANCASILCKCYSTSTIINQSPDKLLTFIASDTCPLVEIDGVTIQVG 420 
AF378705.1      TMGNKFILSKGNIVANCASILCKCYSTSTIINQSPDKLLTFIASDTCPLVEIDGVTIQVG 420 
AF305419.1      TMGNKFILSKGNIVANCASILCKCYSTSTIINQSPDKLLTFIASDTCPLVEIDGATIQVG 420 
X65509.1        TMGNKFILSKGNIVANCASILCKCYSTSTIINQSPDKLLTFIASDTCPLVEIDGATIQVG 420 
                ******************************************************.***** 
 
RecF            GRQYPDMVYEGKVALGPAISPERLDVGTNLGNALKKLDDAKVLIDSSNRILGTVRRSSFN 480 
AF378705.1      GRQYPDMVYEGKVALGPAISLERLDVGTNLGNALKKLDDAKVLIDSSNQILETVRRSSFN 480 
AF305419.1      GRQYPDMVYEGKVALGPAISLDRLDVGTNLGNALKKLDDAKVLIDSSNQILETVRRSSFN 480 
X65509.1        GRQYPDMVYEGKVALGPAISLDRLDVGTNLGNALKKLDDAKVLIDSSNQILETVRRSSFN 480 
                ******************** :**************************:** ******** 
 
RecF            FGSLLSVPILSCTALALLLLIYCCKRRYQQTLEQHTKVDPAFKPDLTGTSKSYVRSH 537 
AF378705.1      FGSLLSVPILSCTALALLLLIYCCKRRYQQTLKQHTKVDPAFKPDLTGTSKSYVRSL 537 
AF305419.1      FGSLLSVPILSCTALALLLLIYCCKRRYQQTLKQHTKVDPAFKPDLTGTSKSYVRSL 537 
X65509.1        FGSLLSVPILSCTALALLLLIYCCKRRYQQTLKQHTKVDPAFKPDLTGTSKSYVRSH 537 





The complete coding region of the F protein of CDV was expressed in Pichia pastoris 
Mice inoculated with the F0 protein produced antibodies that recognized CDV protein 
The recombinant protein could be used as a subunit vaccine against canine distemper 
